Español24/7 enrollment line386-218-5911

What happens here

  • 4 treatment rooms and 5 examination rooms
  • Full-service on-site regulatory department
  • Certified sample-processing lab (refrigerated centrifuges, −70°C and −20°C storage)
  • On-site pharmacy with laminar flow hood for investigational product
  • Bilingual English / Spanish study team

Studies enrolling at this location

EnrollingEndocrinology

Type 2 Diabetes with Obesity

Evaluating a new investigational therapy for adults with Type 2 Diabetes and obesity — measuring weight loss, metabolic health, and glycemic control.

See study
EnrollingPulmonology

COPD with Type 2 Inflammation

Testing Depemokimab — an investigational long-acting anti–IL-5 therapy — to reduce exacerbations in adults with moderate-to-severe COPD.

See study
EnrollingPediatric Endocrinology

Idiopathic Short Stature (ISS) Growth Study

Evaluating Vosoritide, an investigational therapy designed to support bone growth and improve height outcomes in children with Idiopathic Short Stature.

See study
EnrollingPsychiatry

Major Depressive Disorder — Relapse Prevention

Testing Brenipatide alongside standard antidepressant therapy to delay or prevent relapse in adults currently in remission from MDD.

See study
Actively RecruitingMetabolic Health

Adults Living with Obesity (Without Diabetes)

Clinical research evaluating weight management for adults living with obesity who do not have a diabetes diagnosis.

See study
EnrollingEndocrinology

Type 2 Diabetes with Overweight or Obesity (VESPER-5)

A Phase 3 study (VESPER-5) of an investigational ultra-long-acting GLP-1 receptor agonist for adults with overweight or obesity and Type 2 Diabetes.

See study
EnrollingEndocrinology

Type 2 Diabetes with Obesity (AMAZE 8)

An investigational treatment study (AMAZE 8) for adults living with Type 2 Diabetes and overweight or obesity.

See study
EnrollingNeurology

Tardive Dyskinesia

A clinical research study of an investigational treatment for adults with tardive dyskinesia — involuntary, repetitive movements often linked to long-term use of certain psychiatric medications.

See study
EnrollingNeurology

Tardive Dyskinesia — Valbenazine Study

A Phase 4, open-label study of valbenazine for adults with tardive dyskinesia who remain symptomatic on deutetrabenazine or after stopping a prior VMAT2 inhibitor.

See study

Getting here

2541 South Volusia Ave., Suite 100, Orange City, FL 32763. Open in Maps ↗

Every study at this location runs under independent IRB oversight and ICH Good Clinical Practice standards.